Source briefing
Human medicines European public assessment report (EPAR): Izamby, denosumab, Date of authorisation: 26/06/2025, Revision: 3, Status: Authorised
Human medicines European public assessment report (EPAR): Izamby, denosumab, Date of authorisation: 26/06/2025, Revision: 3, Status: Authorised
Read →
Source briefing
Human medicines European public assessment report (EPAR): Chenodeoxycholic acid Leadiant (previously Chenodeoxycholic acid sigma-tau), chenodeoxycholic acid, Date of authorisation: 10/04/2017, Revision: 8, Status: Authorised
Human medicines European public assessment report (EPAR): Chenodeoxycholic acid Leadiant (previously Chenodeoxycholic acid sigma-tau), chenodeoxycholic acid, Date of authorisation: 10/04/2017, Revision: 8, Status: Authorised
Read →
Source briefing
Ross Levine on Blood Cancer, Cancer Genetics, and New Therapies
Ross L. Levine, MD, Chief Scientific Officer at Memorial Sloan Kettering Cancer Center, joins The Future of Medicine for a conversation about blood cancer, cancer genetics, and how a laboratory discovery can eventually lead to new treatments.More than…
Read →Source briefing
Effect of food swap recommendations on the healthfulness and carbon footprint of grocery purchases in a naturalistic online store: A randomized parallel trial
by Anna H. Grummon, Kevin O’Sullivan, Amanda B. Zeitlin, Lindsey Smith Taillie, Cristina J. Y. Lee, Ashe J. Walker, Verena Tiefenbeck, Elgar Fleisch, Clayton Ulm, Thomas N. Robinson Background Modeling studies suggest that simple dietary “swaps” in which…
Read →Source briefing
Making the case for independent science
Med School lecturer nods to wider implications in blueprint for Hungary
Read →Source briefing
Human medicines European public assessment report (EPAR): Cenrifki, tolebrutinib, Date of authorisation: 19/06/2026, Revision: 1, Status: Authorised
Human medicines European public assessment report (EPAR): Cenrifki, tolebrutinib, Date of authorisation: 19/06/2026, Revision: 1, Status: Authorised
Read →Source briefing
Human medicines European public assessment report (EPAR): Rimmyrah, ranibizumab, Date of authorisation: 05/01/2024, Revision: 6, Status: Authorised
Human medicines European public assessment report (EPAR): Rimmyrah, ranibizumab, Date of authorisation: 05/01/2024, Revision: 6, Status: Authorised
Read →Source briefing
Human medicines European public assessment report (EPAR): Ondibta, insulin glargine, Date of authorisation: 09/01/2026, Revision: 3, Status: Authorised
Human medicines European public assessment report (EPAR): Ondibta, insulin glargine, Date of authorisation: 09/01/2026, Revision: 3, Status: Authorised
Read →Source briefing
Communicable disease threats report, 15 – 21 August 2026, week 34
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 15-21 August 2026, and includes updates on Ebola, respiratory virus epidemiology in the EU/EEA, swine flu, West Nile virus, Crimean-Congo haemorrhagic fever, dengue, chikungunya, vibrio,…
Read →Source briefing
Effect of a digital intervention on mental health symptoms in adults with chronic conditions: A three-arm randomized controlled trial
by Emily Johnson, Ashley Hyde, Shaina Corrick, Serena Isley, Gail Wright, Justin Ezekowitz, Yinggan Zheng, Dayna Lee-Baggley, Jude Spiers, John C. Spence, Margaret L. McNeely, Stephanie Thompson, Kathleen Ismond, Sarah Tymchuk, Puneeta Tandon Background Anxiety, depression, and fatigue…
Read →